236 results about "Enterovirus 71" patented technology

The invention describes compositions and methods for recombinant protein expression in a wide range of cell types, including mammalian, insect, and bacterial cells. The compositions comprise a viral IRES sequence selected from enterovirus 71 (EV71), hepatitis C virus (HCV), or encephalomyocarditis virus (EMCV), or a variant or fragment thereof, or alternatively, a homolog of a viral IRES selected from EV71, HCV, or EMCV, or a variant or fragment thereof. Methods of using the compositions are also described.

The invention relates to a caprolactam anti-enterovirus 71 (EV71) 3C protease inhibitor with a structural formula shown as compounds (M). Each variable in the structure is defined as the specification. The compounds can effectively inhibit or block replication of enterovirus 71. The invention relates to discovery and application of compounds comprising a structure of formula (M), various optical isomers thereof, metabolites with pharmaceutically activity, pharmaceutically acceptable salts, solvates and prodrugs in preparing antiviral drugs for treating virus infections of hand-foot-and-mouth diseases. The invention also relates to an intermediate and a synthetic method for preparing the compounds having the structure of the formula (M).

The invention relates to a construction method of an enterovirus 71 type infection model based on hSCARB2 gene knock-in and use of the infection model, and especially provides an effective means for in vivo evaluation of EV71 vaccines and antiviral drugs.

The invention belongs to the field of biotechnology, and relates to a loop-mediated isothermal amplification (LAMP) assay kit of Coxsackie A16 (Cox A16) and Enterovirus 71 (EV 71) which are main pathogens of hand, foot and mouth disease, and an establishment method and an application of the assay kit. The assay kit comprises four LAMP primers and LAMP reaction liquid for detecting Coxsackie A16, and four LAMP primers and LAMP reaction liquid for detecting Enterovirus 71. Tests prove that the assay kit has the advantages of good specificity and sensitivity, rapid amplification rapid, high efficiency and simple identification. A detection system provided by the invention can rapidly, conveniently, efficiently, high specifically and high sensitively detect Coxsackie A16 and Enterovirus 71 without complex apparatuses thus can satisfy well clinical detection requirements of hand, foot and mouth disease, and is suitable for a large-scale promotion and an application.

The invention provides an enterovirus 71 complete genome sequence, comprising a nucleotide sequence shown by SEQ ID NO:1. The sequence can be used for preparing a vaccine for preventing the enterovirus 71 and a neutralizing antibody for resisting the enterovirus 71, provides impersonal basis for further acquiring EV71 genetic derivation in South China, provides reliable data information for developing diagnostic reagents and vaccines of enzyme-linked immunosorbent assay (ELISA) for outbreak people in different areas of China, and provides valuable resource for deeply studying genetic variation rules of EV71 and mechanism causing hand-foot-and-mouth disease.

The invention provides a combined vaccine for preventing a hand-foot-mouth disease. The combined vaccine contains an inactivated EV71 (Enterovirus 71) antigen, an inactivated CA16 (Coxasckievirus A16) antigen and an inactivated CA10 (Coxasckievirus A10) antigen. The hand-foot-mouth disease preventing combined vaccine with good immunogenicity, high safety and high stability is prepared by culturing main epidemic virus strains, namely an EV71 type, a CA16 type and a CA10 type, which cause the hand-foot-mouth disease, performing ultrafiltration concentration, performing sucrose density gradient centrifugation, performing ultrafiltration desugarization and performing sterilization filtration to obtain a purified virus solution, and further preparing the virus solution into the combined vaccine. The combined vaccine provided by the invention can prevent infection of a variety of enteroviruses to a human body at the same time, and a phenomenon of mutual interference among the antigens does not exist and the corresponding immunogenicity is not lower than that excited by a single antigen; after use of the combined vaccine provided by the invention, a vaccinating procedure can be significantly simplified, the vaccinating efficiency is improved and the cost is reduced.